Study of tagraxofusp reports 90 percent response rate for deadly blood cancer with no prior available therapies
An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD…
Browsing: blastic plasmacytoid dendritic cell neoplasm
Investigational drug shows promising results in Phase II study of aggressive, often fatal blood disorder with no approved therapies
A Phase I/II study, led by investigators at The University of Texas MD Anderson Cancer…